Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684109 · ClinicalTrials.gov registry record · NA
Non-invasive Glioma Characterization Through Molecular Imaging
A NA study of Glioma and Brain Tumor, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03684109: Recruiting NA study of Glioma and Brain Tumor, sponsored by University of Miami.
NCT03684109 is a NA study of Glioma and Brain Tumor that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03684109, a NA study of Glioma and Brain Tumor, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
Primary Outcome
2HG concentrations as measured via 3T MRI Scanner.
Conditions Studied
Interventions
- DEVICE 3T MRI Scanner
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
What NCT03684109 shows while recruiting
NCT03684109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 3T MRI Scanner is the first listed.
NCT03684109 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03684109 about?
NCT03684109 is a clinical study titled "Non-invasive Glioma Characterization Through Molecular Imaging". MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
What is the current status of trial NCT03684109?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-01-25. Estimated completion is 2026-01-31.
What conditions does trial NCT03684109 study?
This clinical trial studies the following conditions: Glioma, Brain Tumor, Malignant Glioma, Primary Brain Tumor, Malignant Primary Brain Tumor.
What interventions are being tested in trial NCT03684109?
The interventions under investigation include: 3T MRI Scanner (DEVICE).
Who is sponsoring clinical trial NCT03684109?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684109 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03684109's enrollment target sits among peer trials
30 53rd of 87 higher than 31 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI